Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles

QR Code

Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles

Barbara Colzani,1,* Laura Pandolfi,1,* Ada Hoti,1 Pietro Alessandro Iovene,1 Antonino Natalello,1 Svetlana Avvakumova,1 Miriam Colombo,1 Davide Prosperi1,2 1Department of Biotechnology and Biosciences, University of Milano Bicocca, Milano, Italy; 2Nanomedicine Laboratory, ICS Maugeri S. p. A. SB, P...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Colzani B, Pandolfi L, Hoti A, Iovene PA, Natalello A, Avvakumova S, Colombo M, Prosperi D
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2018
Sujets:	biocompatible nanoparticles ADCC HER2-positive breast cancer immunotherapy chemotherapy. Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/7841875efdfd460e843d809544d49318
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
par: Nathalie I. Bouwer, et autres
Publié: (2021)

The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
par: Andrea Villasco, et autres
Publié: (2021)

Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells
par: Rodríguez-Serrano F, et autres
Publié: (2016)

Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle
par: Zhang C, et autres
Publié: (2020)

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer
par: Rodallec A, et autres
Publié: (2018)

Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab
par: Martins,Sandro José, et autres
Publié: (2012)

AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer
par: Long Wang, et autres
Publié: (2021)

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
par: Antolín S, et autres
Publié: (2018)

In vitro evaluation of the antitumor effect of bismuth lipophilic nanoparticles (BisBAL NPs) on breast cancer cells
par: Hernandez-Delgadillo R, et autres
Publié: (2018)

Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo
par: Duan D, et autres
Publié: (2018)

Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study
par: Eliza D. Hompe, et autres
Publié: (2019)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
par: Jagosky M, et autres
Publié: (2021)

Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses
par: Jonathan Richard, et autres
Publié: (2018)

99mTc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer
par: Rainone P, et autres
Publié: (2021)

The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
par: Ilana Schlam, et autres
Publié: (2021)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
par: Ayoub NM, et autres
Publié: (2019)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
par: Li J, et autres
Publié: (2017)

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods
par: Saglican,Yesim, et autres
Publié: (2015)

Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
par: DESRIANI DESRIANI, et autres
Publié: (2016)

Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects
par: Franck P. Dupuy, et autres
Publié: (2019)

Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
par: Serafin Morales, et autres
Publié: (2021)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
par: Puhalla S, et autres
Publié: (2016)

Synthesis of biocompatible iron oxide nanoparticles as a drug delivery vehicle
par: Kansara K, et autres
Publié: (2018)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
par: Chao Li, et autres
Publié: (2021)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
par: Matteo Allegretti, et autres
Publié: (2021)

Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
par: Jin-xiu Zhong, et autres
Publié: (2021)

Ejercicio físico en mujeres con cáncer de mama
par: MOROS,Mª TERESA, et autres
Publié: (2010)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
par: Phung HT, et autres
Publié: (2020)

Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for <italic toggle="yes">In Vivo</italic> Protection in a Serum Transfer Mouse Challenge Model
par: Henning Jacobsen, et autres
Publié: (2017)

An institutional review of tumour biology of breast cancer in young Nepalese women
par: Bikash Nepal, et autres
Publié: (2017)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
par: Diana B. Peckys, et autres
Publié: (2021)

Large‐scale genomic sequencing reveals adaptive opportunity of targeting mutated‐PI3Kα in early and advanced HER2‐positive breast cancer
par: Lin‐Wei Guo, et autres
Publié: (2021)

Banana Peel-Derived Dendrite-Shaped Au Nanomaterials with Dual Inhibition Toward Tumor Growth and Migration
par: Liu Y, et autres
Publié: (2020)

Perfiles de expresión génica en decisiones terapéuticas en cáncer de mama
par: Corvalán,Alejandro
Publié: (2007)

Terapia endocrina neoadyuvante en cáncer de mama, una alternativa de tratamiento e investigación
par: Acevedo,Francisco, et autres
Publié: (2013)

Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses
par: Jérémie Prévost, et autres
Publié: (2019)

Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
par: Editorial Board
Publié: (2021)

Neoadjuvant Therapy Using Checkpoint Inhibitors before Radical Cystectomy for Muscle Invasive Bladder Cancer: A Systematic Review
par: Hadi SHSM, et autres
Publié: (2021)

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
par: Yucheol Cheong, et autres
Publié: (2021)

Inmunohistoquímica convencional como predictor de respuesta y sobrevida en pacientes con cáncer de mama tratadas con quimioterapia preoperatoria: Experiencia de un centro
par: Acevedo,Francisco, et autres
Publié: (2015)